Latest news

Thumbnail image for Gov’t announces £3.5bn a year for primary, community care

Gov’t announces £3.5bn a year for primary, community care

The government has announced plans to inject an extra £3.5 billion a year into primary and community healthcare by 2023/24, calling the investment a “historic commitment” to increasing the proportion of NHS funding spent on primary and community services.

23rd November 2018

Thumbnail image for Pennsylvania Uni brings Penn Medicine to London

Pennsylvania Uni brings Penn Medicine to London

Penn Medicine has launched its first European presence in London, in a move that aims to expand access to innovations pioneered by its physicians in the US to patients in the UK and Europe.

23rd November 2018

Thumbnail image for GSK retains leading position on access to medicines list

GSK retains leading position on access to medicines list

GlaxoSmithKline has retained its top position among a global list of pharmaceutical companies striving to make their medicines, vaccines and diagnostics more accessible for people in low- and middle-income countries.

21st November 2018

Thumbnail image for European Commission approves Lilly's Emgality for migraine

European Commission approves Lilly's Emgality for migraine

Eli Lilly has confirmed that Emgality, a once-monthly monoclonal antibody injection, has been approved by the European Commission for preventive treatment of migraine in adults who have at least four migraine days per month.

21st November 2018

Thumbnail image for First Rare Disease Collaborative Network for refractory coeliac disease

First Rare Disease Collaborative Network for refractory coeliac disease

Refractory coeliac disease, a deadly form of the autoimmune condition coeliac disease, has received its first dedicated support from NHS England, with the setting up of a Rare Disease Collaborative Network (RDCN) to accelerate research and treatment into this life threatening condition.

20th November 2018

Thumbnail image for GSK files Nucala for wider paediatric use

GSK files Nucala for wider paediatric use

GlaxoSmithKline is seeking to expand the use of its biologic Nucala in the US to include children aged six to 11 years with severe eosinophilic asthma.

20th November 2018

Previous  --   2 3 4 5 6 7 8 9 10 11   --  Next

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download